slt

MaryLou Stroumbos

Executive Vice President, Regulatory Affairs

Experience and Expertise

MaryLou Stroumbos is executive vice president of regulatory affairs at Sirtex. She is responsible for driving the strategic direction of our global quality and regulatory affairs programs and enabling commercialization of innovative medical devices.

As a licensed attorney and regulatory affairs professional, MaryLou has supported strategic business operations and regulatory planning within the medical device industry for nearly 20 years. Before joining Sirtex in 2018, MaryLou served as director of regulatory affairs at Mitralign, Inc., where she was responsible for obtaining regulatory approvals for a novel class III cardiovascular implant device. Prior to that role she spent nine years at NxStage Medical, Inc. working in positions of increasing responsibility within the regulatory department, eventually becoming director of regulatory affairs.

MaryLou received a J.D. from Suffolk University Law School, an MBA from Rivier University, and a bachelor’s degree in business administration from the University of Massachusetts at Lowell. She also completed the Regulatory Affairs Professional Society Executive Development Program at Northwestern University's Kellogg School of Management. 





slt
Kevin R. Smith
CEO

slt
Paul Andreassi
Executive Vice President of Global Quality Assurance

slt
Jesse Hansen
Global Head of Marketing

slt
Francis Jannot
Executive Vice President of International Sales

slt
Cathleen Lowndes
Chief Human Resources Officer

slt
Amy Pan
Chief Financial Officer

slt
Suki Shergill
Executive Vice President, Global Pricing & Market Access

slt
Kevin P. Smith
General Counsel & Executive Vice President, Business Development

slt
Grant Spindler
Global Head of Operations

slt
MaryLou Stroumbos
Executive Vice President, Regulatory Affairs

slt
Mark Turco
Global Chief Medical Officer & Executive Vice President of Research & Development



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok